Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

NCT04046445 is registered in ClinicalTrials.gov with Amal Therapeutics as lead sponsor.

NCT NCT04046445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04046445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
Lead sponsor
Amal Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 22, 2019
Completion date
August 31, 2025
Enrollment
96 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, liver metastasis colon cancer, metastatic colorectal cancer, mss, stage iv colon cancer, stage iv rectal cancer